Benefits
Reduced cold and flu duration
Meta-analyses of RCTs show elderberry supplementation reduces duration of cold and influenza by an average of 2–4 days and significantly reduces symptom severity scores.
Antiviral activity
Elderberry flavonoids bind directly to influenza virion surface proteins, inhibiting viral entry into host cells. Also demonstrated activity against H1N1, H5N1, and some SARS-CoV-2 variants in vitro.
Immune stimulation
Stimulates production of inflammatory cytokines in healthy immune cells, priming the immune system for faster response to pathogens. This pro-inflammatory effect is beneficial in healthy individuals.
Antioxidant protection
Anthocyanins have among the highest antioxidant activity of any fruit polyphenol, reducing oxidative stress markers and protecting cells from free radical damage.
Mechanism of action
Viral hemagglutinin inhibition
Elderberry polyphenols bind to influenza hemagglutinin, the surface protein responsible for viral attachment to host cell sialic acid receptors. This blocks viral entry and reduces infectivity.
Cytokine induction
Elderberry activates monocytes and macrophages to produce pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6, accelerating innate immune response during acute infection.
Neuraminidase inhibition
Flavonoids from elderberry inhibit neuraminidase, the enzyme influenza virus uses to release newly formed virions from infected cells, reducing viral spread within the respiratory tract.
Clinical trials
Pooled analysis of 4 randomized controlled trials (Complement Ther Med — or related elderberry pooled analyses) examining black elderberry (Sambucus nigra) supplementation for upper respiratory symptoms.
Pooled across 4 clinical trials.
Elderberry supplementation reduced upper respiratory symptom duration vs placebo, with effect more pronounced for influenza-like illness than non-influenza colds. Effect sizes meaningful but trials were generally small. Note: a major 2019 evidence review (Hawkins et al.) found pooled benefit; subsequent independent replications have been more mixed. Recent COVID-era trials of elderberry for respiratory infection prevention have been less impressive.
Randomized controlled trial of elderberry extract (Sambucol®, 15 mL four times daily) vs placebo in 60 patients with confirmed influenza A or B within 48 hours of symptom onset. (Zakay-, J Int Med Res)
60 patients with confirmed influenza.
Recovery was an average of 4 days earlier in elderberry group vs placebo. Significant reductions in fever, headache, muscle aches, nasal congestion, and cough. Critical caveat: small trial (n=60), conducted by Israeli investigators with industry connection to Sambucol®. Larger independent replication has been limited. The 4-day recovery improvement is impressive but should be tempered by trial size and subsequent mixed evidence. Modern flu antivirals (oseltamivir) provide ~1-day reduction — comparable elderberry effects would be remarkable but require confirmation.